Skip to content 
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida. more
| Time Frame | HCWB | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 353.1% | 7.12% | -0.74% |
| 1-Month Return | 161.49% | 7.54% | -2.08% |
| 3-Month Return | 1356.36% | 11.76% | 17.23% |
| 6-Month Return | 320.48% | 3.16% | 7.65% |
| 1-Year Return | 32.56% | 19.25% | 19.89% |
| 3-Year Return | -94.05% | 22.35% | 69.19% |
| 5-Year Return | -97.91% | 27.54% | 73.21% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 4.10M | 6.72M | 2.84M | 2.57M | 54.23K | [{"date":"2021-12-31","value":60.99,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":42.28,"profit":true},{"date":"2024-12-31","value":38.18,"profit":true},{"date":"2025-12-31","value":0.81,"profit":true}] |
| Cost of Revenue | 543.60K | 4.14M | 2.28M | 1.61M | 43.39K | [{"date":"2021-12-31","value":13.14,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":55.16,"profit":true},{"date":"2024-12-31","value":38.87,"profit":true},{"date":"2025-12-31","value":1.05,"profit":true}] |
| Gross Profit | (543.60K) | 2.59M | 560.36K | 959.40K | 10.85K | [{"date":"2021-12-31","value":-21.02,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":21.67,"profit":true},{"date":"2024-12-31","value":37.09,"profit":true},{"date":"2025-12-31","value":0.42,"profit":true}] |
| Gross Margin | (13.26%) | 38.48% | 19.72% | 37.38% | 20.00% | [{"date":"2021-12-31","value":-34.46,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":51.25,"profit":true},{"date":"2024-12-31","value":97.15,"profit":true},{"date":"2025-12-31","value":51.98,"profit":true}] |
| Operating Expenses | 13.37M | 17.67M | 26.28M | 30.44M | 11.27M | [{"date":"2021-12-31","value":43.92,"profit":true},{"date":"2022-12-31","value":58.03,"profit":true},{"date":"2023-12-31","value":86.33,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":37.02,"profit":true}] |
| Operating Income | (13.37M) | (15.08M) | (25.72M) | (29.48M) | (11.26M) | [{"date":"2021-12-31","value":-1336783400,"profit":false},{"date":"2022-12-31","value":-1507877800,"profit":false},{"date":"2023-12-31","value":-2571716000,"profit":false},{"date":"2024-12-31","value":-2947966700,"profit":false},{"date":"2025-12-31","value":-1125728800,"profit":false}] |
| Total Non-Operating Income/Expense | 1.01M | 51.41K | 343.94K | (1.70M) | 2.05M | [{"date":"2021-12-31","value":49.37,"profit":true},{"date":"2022-12-31","value":2.51,"profit":true},{"date":"2023-12-31","value":16.8,"profit":true},{"date":"2024-12-31","value":-83.16,"profit":false},{"date":"2025-12-31","value":100,"profit":true}] |
| Pre-Tax Income | (12.86M) | (14.90M) | (24.99M) | (30.02M) | (7.96M) | [{"date":"2021-12-31","value":-1286246800,"profit":false},{"date":"2022-12-31","value":-1490070300,"profit":false},{"date":"2023-12-31","value":-2499427700,"profit":false},{"date":"2024-12-31","value":-3002381400,"profit":false},{"date":"2025-12-31","value":-795970900,"profit":false}] |
| Income Taxes | (505.37K) | (178.07K) | (4.00) | - | - | [{"date":"2021-12-31","value":-50536600,"profit":false},{"date":"2022-12-31","value":-17807500,"profit":false},{"date":"2023-12-31","value":-400,"profit":false},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income After Taxes | (12.36M) | (14.72M) | (24.99M) | - | - | [{"date":"2021-12-31","value":-1235710200,"profit":false},{"date":"2022-12-31","value":-1472262800,"profit":false},{"date":"2023-12-31","value":-2499427300,"profit":false},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | (12.86M) | (15.21M) | (19.73M) | (30.02M) | (7.96M) | [{"date":"2021-12-31","value":-1286246800,"profit":false},{"date":"2022-12-31","value":-1520543800,"profit":false},{"date":"2023-12-31","value":-1973248700,"profit":false},{"date":"2024-12-31","value":-3002381400,"profit":false},{"date":"2025-12-31","value":-795970900,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | (12.86M) | (14.90M) | (24.99M) | (30.02M) | (7.96M) | [{"date":"2021-12-31","value":-1286246800,"profit":false},{"date":"2022-12-31","value":-1490070300,"profit":false},{"date":"2023-12-31","value":-2499427700,"profit":false},{"date":"2024-12-31","value":-3002381400,"profit":false},{"date":"2025-12-31","value":-795970900,"profit":false}] |
| EPS (Diluted) | (1.11) | (0.42) | (0.70) | (7.68) | (9.88) | [{"date":"2021-12-31","value":-110.7,"profit":false},{"date":"2022-12-31","value":-42,"profit":false},{"date":"2023-12-31","value":-70,"profit":false},{"date":"2024-12-31","value":-768,"profit":false},{"date":"2025-12-31","value":-988,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| HCWB | |
|---|---|
| Cash Ratio | 0.06 |
| Current Ratio | 0.09 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| HCWB | |
|---|---|
| ROA (LTM) | -15.06% |
| ROE (LTM) | -27725.96% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| HCWB | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.79 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.21 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| HCWB | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 1.12 |
| P/B | 1.29 |
| Price/FCF | NM |
| EV/R | 1.94 |
| EV/Ebitda | NM |
HCW Biologics Inc (HCWB) share price today is $5.14
Yes, Indians can buy shares of HCW Biologics Inc (HCWB) on Vested. To buy
Yes, you can purchase fractional shares of HCW Biologics Inc (HCWB) via the Vested app. You can start investing in HCW Biologics Inc (HCWB) with a minimum investment of $1.
You can invest in shares of HCW Biologics Inc (HCWB) via Vested in three simple steps:
The 52-week high price of HCW Biologics Inc (HCWB) is $44.1. The 52-week low price of HCW Biologics Inc (HCWB) is $1.5.
The price-to-earnings (P/E) ratio of HCW Biologics Inc (HCWB) is
The price-to-book (P/B) ratio of HCW Biologics Inc (HCWB) is 1.29
The dividend yield of HCW Biologics Inc (HCWB) is 0.00%
The market capitalization of HCW Biologics Inc (HCWB) is $7.38M
The stock symbol (or ticker) of HCW Biologics Inc is HCWB
Consider the share price of HCW Biologics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether HCW Biologics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in HCW Biologics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the HCW Biologics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of HCW Biologics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that HCW Biologics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
